BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aguiar BF, Campos GRF, Rodrigues JPV, Marques NN, Molina BF, Bittar C, Souza FF, Martinelli ALC, Rahal P, Pereira LRL. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil. Clin Res Hepatol Gastroenterol 2020;44:329-39. [PMID: 31523019 DOI: 10.1016/j.clinre.2019.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 da Silva DL, Nunes HM, Freitas PEB. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil. Virus Res 2021;292:198251. [PMID: 33259871 DOI: 10.1016/j.virusres.2020.198251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ferreira VL, Leonart LP, Pedroso MLA, Pontarolo R. Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil. Rev Soc Bras Med Trop 2020;53:e20190594. [PMID: 32578707 DOI: 10.1590/0037-8682-0594-2019] [Reference Citation Analysis]
3 Cabral BCA, Ramos JA, Silveira ALM, Nascimento ÉRDS, Ferreira SB, Coelho HSM, Moura-Neto RS, Villela-Nogueira CA, Hoffmann L, Silva R. Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals. Int J Infect Dis 2021;115:171-7. [PMID: 34902582 DOI: 10.1016/j.ijid.2021.12.320] [Reference Citation Analysis]